BLISS GVS PHARMA LTD.

Bliss GVS Pharma Ltd. announced significant management changes following a Board of Directors meeting on July 3, 2026. Mr. Santosh Parab has been appointed as an Additional Director (Non-Executive Non-Independent) effective July 3, 2026. Additionally, Mr. Rahul Adakmol will take over as the Chief Executive Officer from July 15, 2026. Mr. Narsimha Shibroor Kamath will step down as CEO on July 14, 2026, but will continue in his role as Managing Director. These appointments aim to strengthen the company's leadership and strategic direction.

Bliss GVS Pharma Ltd announced key management changes following a Board of Directors meeting held on July 3, 2026. Mr. Santosh Parab has been appointed as an Additional Director (Non-Executive Non-Independent) effective July 3, 2026. Additionally, Mr. Rahul Adakmol will take over as the Chief Executive Officer from July 15, 2026. Mr. Narsimha Shibroor Kamath will step down as CEO on July 14, 2026, but will continue as Managing Director. The company provided brief profiles for the new appointees.

Bliss GVS Pharma Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will continue until 48 hours after the announcement of the unaudited financial results for the quarter ended June 30, 2026. The decision is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Insiders, designated persons, and their immediate relatives are prohibited from trading in the company's shares during this period. The date for the board meeting to approve these financial results will be communicated separately.

Bliss GVS Pharma Ltd has announced the fixation of the record date for the payment of its final dividend for the financial year ended March 31, 2026. The company's Register of Members and Share Transfer Books will be closed from July 9, 2026, to July 15, 2026, inclusive. The record date for dividend payment is set for July 8, 2026. This period also coincides with the closure for the 41st Annual General Meeting, scheduled for July 15, 2026, where the final dividend, if approved, will be discussed. The dividend distribution is expected to be completed by August 14, 2026.

Bliss GVS Pharma Limited has announced its 41st Annual General Meeting (AGM) will be held on Wednesday, July 15, 2026, at 11:00 AM IST via Video Conference/Other Audio-Visual Means. The company has fixed Wednesday, July 08, 2026, as the Record Date for determining entitlement to the final dividend for the financial year ended March 31, 2026. The proposed final dividend is 100% or ₹1.00 per equity share. If approved at the AGM, the dividend payment is expected on or before Friday, August 14, 2026. The AGM agenda includes adopting financial statements and re-appointing Mr. Narsimha Shibroor Kamath as Managing Director & CEO.

Bliss GVS Pharma Ltd has filed the Notice convening its 41st Annual General Meeting (AGM) and the Annual Report for the financial year 2025-2026. The AGM is scheduled for July 15, 2026, to be held via Video Conference/Other Audio-Visual Means. The company has also fixed July 8, 2026, as the Record Date for determining member entitlement to the final dividend for FY 2025-26. If approved at the AGM, the dividend payment is expected by August 14, 2026. Both the AGM Notice and Annual Report are being sent electronically to members and are available on the company's website.

Bliss GVS Pharma Ltd has issued a communication to its shareholders regarding the tax deduction on dividends. Following the abolition of dividend distribution tax and its taxation in the hands of shareholders as per the Finance Act, 2020, the company will deduct tax at source (TDS) on dividends if approved at the upcoming 41st AGM. The recommended final dividend is Re. 1.00 per equity share for FY 2025-26, with July 8, 2026, set as the record date. TDS rates will vary based on shareholder status and documentation, with specific provisions outlined for resident individuals and non-individuals, including exemptions for certain entities and thresholds.

Bliss GVS Pharma Limited has received a Draft Letter of Offer (DLOF) from SBI Capital Markets Limited, the Manager to the Open Offer. The offer is being made by Anupam Rasayan India Limited to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma, representing 26.00% of the expanded voting share capital, at a price of ₹299.00 per share. The DLOF has been filed with SEBI and contains the detailed terms and conditions of the Open Offer, following previous announcements on May 23, May 30, and June 01, 2026.

SBI Capital Markets Ltd, acting as the Manager to the Open Offer, has submitted a Draft Letter of Offer to the BSE for the public shareholders of Bliss GVS Pharma Ltd. Anupam Rasayan India Limited is making a cash offer to acquire up to 2,77,26,848 equity shares, representing 26.00% of the expanded voting share capital, at an offer price of ₹299.00 per share. This open offer is being made in compliance with SEBI (SAST) Regulations, 2011. The submission follows previous public announcements and detailed statements regarding the offer.

Bliss GVS Pharma Limited has disclosed that promoter Gagan Harsh Sharma sold 2,17,123 equity shares of the company through an open market transaction on May 18, 2026. This disclosure was made in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.